Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese
Year:
Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.